Skip to main content
Clinical Trials/ACTRN12612000535875
ACTRN12612000535875
Completed
Phase 1

In paediatric patients with high risk brain tumours, is it safe and feasible to infuse autologous Peripheral Blood Stem Cells transduced with a mutant MGMT Gene?

The Sydney Children's Hospital Network0 sites12 target enrollmentMay 21, 2012

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Childhood Brain Tumours
Sponsor
The Sydney Children's Hospital Network
Enrollment
12
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 21, 2012
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
The Sydney Children's Hospital Network

Eligibility Criteria

Inclusion Criteria

  • 1\. Patient diagnosed with one of the following:
  • a) High grade glioma which has progessed or recurred following standard therapy
  • b) Medulloblastoma which has recurred following conventional therapy
  • c) Ependymoma which has recurred following maximal safe surgical resection and radiotherapy, and where maximal safe re\-section and re\-irradiation has been undertaken or considered not appropriate
  • d) Atypical teratoid/rhabdoid tumour which has recurred
  • e) Low grade glioma which has recurred
  • f) Brainstem glioma of diffuse pontine type
  • 2\. Life expectancy greater than or equal to 8 weeks
  • 3\. No severe uncontrolled infection
  • 4\. Performance status :

Exclusion Criteria

  • 1\. Uncontrolled infection
  • 2\. Malignant infiltration of the bone marrow or any other site outside the central nervous system

Outcomes

Primary Outcomes

Not specified

Similar Trials